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OBJECTIVES We sought to investigate whether raloxifene reduces ischemia-reperfusion injury and what
mechanisms are involved in the cardioprotective effects.
BACKGROUND Estradiol-17-beta reduces myocardial infarct size in ischemia-reperfusion injury. Raloxifene,
a selective estrogen receptor modulator, demonstrates immediate coronary artery vasorelaxing
effects.
METHODS The myocardial ischemia-reperfusion model included anesthetized open-chest dogs after
90-min occlusion of the left anterior descending coronary artery (LAD) and subsequent 6-h
reperfusion. Raloxifene and/or other drugs were infused into the LAD from 10 min before
coronary occlusion to 1 h after reperfusion without an occlusion period.
RESULTS Infarct size was reduced in the raloxifene (5 g/kg per min) group compared with the control
group (7.2 2.5% vs. 40.9 3.9% of the area at risk, p 0.01). Either NG-nitro-L-arginine
methyl ester (L-NAME), the inhibitor of nitric oxide (NO) synthase, or charybdotoxin, the
blocker of Ca2-activated K (KCa) channels, partially attenuated the infarct size–limiting
effect, and both of them completely abolished the effect. The incidence of ventricular
fibrillation was also less in the raloxifene group than in the control group (11% vs. 44%, p 
0.05). Activity of p38 mitogen-activated protein (MAP) kinase increased with 15-min
ischemia, and raloxifene pretreatment inhibited the activity. Myeloperoxidase activity of the
6-h reperfused myocardium was also attenuated by raloxifene.
CONCLUSIONS These data demonstrate that raloxifene reduces myocardial ischemia-reperfusion injury by
mechanisms dependent on NO and the opening of KCa channels in canine hearts.
Deactivation of p38 MAP kinase and myeloperoxidase by raloxifene may be involved in the
cellular mechanisms of cardioprotection. (J Am Coll Cardiol 2002;40:998–1005) © 2002
by the American College of Cardiology Foundation
Estrogen replacement therapy may reduce cardiovascular
events in postmenopausal women (1). We have previously
demonstrated that estradiol-17-beta reduced the myocardial
infarct (MI) size and the occurrence of ischemia- and
reperfusion-induced ventricular arrhythmias (2) and that it
increased coronary blood flow in canine ischemic hearts (3).
These effects are mediated by both estrogen-induced en-
hancement of nitric oxide (NO) production and the prob-
ability of open Ca2-activated K (KCa) channels. Despite
these beneficial effects, estrogen replacement therapy ap-
pears to increase the risk of endometrial or breast cancer and
may be associated with an increased risk of venous throm-
boembolism (4,5). Raloxifene, one of the selective estrogen
receptor modulators, exerts estrogenic agonistic or antago-
nistic actions on different tissues and has been recently
introduced as a drug for new hormone replacement therapy
because of the reduced adverse effects of estrogen. It
prevents bone loss and has lipid-lowering effects in humans
(6–10). Although it also exhibits coronary-relaxing effects
on the coronary artery in vitro (11), it remains unclear whether
raloxifene has beneficial effects during ischemia and reperfusion
in vivo. If raloxifene does not mediate cardioprotection, as
estradiol-17-beta does, the rationale for the use of raloxifene as
hormone replacement therapy may be weakened.
Therefore, we investigated the effects of raloxifene on MI
size and the occurrence of ischemia- and reperfusion-
induced ventricular arrhythmias. We infused raloxifene into
the coronary artery of open-chest dogs and also examined
whether the effects are involved in NO or the opening of
KCa channels. Furthermore, we also examined the activities
of three major mitogen-activated protein (MAP) kinases—
p38 MAP kinase, c-Jun NH2-terminal protein kinase (JNK)
and extracellular signal–regulated protein kinase (ERK)—
during ischemia, because these MAP kinases are known to
be the mechanism of cellular signaling for cardiac injury and
protection (12–16).
METHODS
Instrumentation. Seventy-four beagle dogs weighing 8 to
12 kg were anesthetized with intravenous sodium pentobar-
From the *Department of Internal Medicine and Therapeutics, Osaka University
Graduate School of Medicine, Suita; †Department of Physiological Science, Tokai
University School of Medicine, Isehara; and ‡Cardiovascular Division of Medicine
and the §Department of Cardiac Physiology, National Cardiovascular Center, Suita,
Japan. This study was partially supported by Comprehensive Research on Aging and
Health, Ministry of Health and Welfare, Grants-in-Aid for Scientific Research (nos.
12470153 and 12877107) for the Ministry of Education, Culture, Sports, Science and
Technology and by the Smoking Research Foundation in Japan.
Manuscript received April 30, 2001; revised manuscript received April 29, 2002,
accepted May 24, 2002.
Journal of the American College of Cardiology Vol. 40, No. 5, 2002
© 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(02)02056-9
bital (30 mg/kg), intubated with a cuffed endotracheal tube
and ventilated with room air mixed with oxygen (1.5 l/min)
with the use of a respirator. Intravenous infusion of sodium
pentobarbital (approximately 30 mg/h) was continued dur-
ing the experimental protocol to maintain hemodynamic
stabilization. The method of preparation for the experi-
ments of ischemia-reperfusion injury in the canine heart was
previously described (2). Briefly, the left anterior descending
coronary artery (LAD) was cannulated and perfused with
blood through an extracorporeal tube from the left carotid
artery. The femoral artery and left atrium were cannulated
to obtain a reference blood flow sample for calculation of the
regional myocardial blood flow and to inject microspheres,
respectively. Heparin (500 U/kg) was administered intrave-
nously every 3 h throughout the protocol. All studies
conformed with the position of the National Institutes of
Health (NIH), in its Guide for the Care and Use of
Laboratory Animals, adopted in November 1984.
Experimental protocols. PROTOCOL 1: EFFECTS OF RALOX-
I F E N E O N I N F A R C T S I Z E A N D I S C H E M I A - A N D
REPERFUSION-INDUCED VENTRICULAR ARRHYTHMIAS.
After hemodynamic stabilization, infusion of raloxifene (0.5
or 5 g/kg per min; Eli Lilly, Indianapolis, Indiana), vehicle
(0.1% [vol/vol] dimethyl sulfoxide) or saline (control group)
was initiated into the bypass tube 10 min before coronary
occlusion and continued until 1 h after reperfusion without
the occlusion period (control group: n  9; vehicle group: n
 9; raloxifene groups: 0.5 g/kg per min, n  6 and 5
g/kg per min, n  9). The intracoronary infusion of 5
g/kg per min of raloxifene theoretically corresponded to 1
mol/l in the coronary artery blood, which was shown in a
previous study to maximally relax the coronary arteries (11),
and 0.5 g/kg per min of raloxifene was also infused to
examine the dose-dependent effects of raloxifene.
In 10-min infusion, the coronary artery was occluded for
90 min and then reperfused for 6 h. Hemodynamic
variables were measured before the administration of
drugs and sustained ischemia at 10 and 90 min after the
onset of ischemia and at 1, 3, and 6 h after the onset of
reperfusion.
PROTOCOL 2: ROLE OF NO AND KCA CHANNELS IN
RALOXIFENE-INDUCED ATTENUATION OF INFARCT SIZE
AND INCIDENCE OF ISCHEMIA- AND REPERFUSION-
INDUCED VENTRICULAR ARRHYTHMIAS. The effects of
raloxifene were examined in dogs pretreated with NG-nitro-
L-arginine methyl ester (L-NAME, an inhibitor of NO
synthase) or charybdotoxin (CTX, a blocker of KCa chan-
nels). Infusion of either L-NAME (10 g/kg per min;
Sigma) or CTX (1 g/kg per min; Sigma, St. Louis,
Missouri) into the bypass tube was initiated 10 min before
infusion of raloxifene (5 g/kg per min) and continued until
1 h of reperfusion after the 90-min occlusion period
(raloxifene  L-NAME group, n  7; raloxifene  CTX
group, n  7; raloxifene  L-NAME  CTX group, n 
7). To examine the effects of inhibitors of ischemia-
reperfusion injury, we also infused only L-NAME and CTX
(n  8) into the bypass tube during the same period as
described earlier. The dose of L-NAME completely abol-
ished the release of NO (17), and the dose of CTX also
maximally attenuated bradykinin-induced coronary vasodi-
lation (18). Hemodynamic variables were measured at the
same time as in protocol 1.
PROTOCOL 3: EFFECTS OF RALOXIFENE ON MAP KINASE
ACTIVITY DURING ISCHEMIA. We used 12 dogs in this
protocol and classified them into four groups: no ischemia,
ischemia, 10-min pretreatment with raloxifene before isch-
emia and 10-min pretreatment with raloxifene, L-NAME
and CTX before ischemia. In the group with no ischemia,
the LAD of three dogs was cannulated and perfused with
blood through a bypass tube for 25 min. In the group with
ischemia, the tube was occluded for 15 min after 10 min of
hemodynamic stabilization, and in the group with raloxifene
pretreatment or raloxifene plus inhibitors pretreatment be-
fore ischemia, 10-min infusion of raloxifene with or without
L-NAME and CTX into the LAD was performed before 15
min of complete coronary artery occlusion. After these
procedures were done, we sacrificed the dogs, excised the
hearts and quickly sampled myocardial tissue supplied by
the LAD into liquid nitrogen and stored 80°C.
Criteria for exclusion. To ensure that all of the animals
included in the analysis of infarct size data were healthy and
exposed to similar degrees of ischemia, we adopted the
following criteria for the exclusion of unsatisfactory dogs: 1)
subendocardial collateral flow 15 ml/100 g per min; 2)
heart rate170 beats/min; or 3) more than two consecutive
attempts required to correct ventricular fibrillation (VF)
with low-energy, direct-current pulses applied directly to
the heart. We calculated the survival percentage as the number
of dogs that survived/number of assigned dogs  100.
Measurement of infarct size and regional myocardial
blood flow. We measured infarct size as previously de-
scribed (2). Briefly, after 6 h of reperfusion, we re-occluded
the LAD and injected Evans’ blue dye into a systemic vein.
Then, the sliced LAD was incubated in 1% 2,3,5-
Triphenyltetrazolium chloride (Sigma) solution to detect the
Abbreviations and Acronyms
CTX  charybdotoxin
ERK  extracellular signal–regulated protein kinase
JNK  c-Jun NH2-terminal protein kinase
KCa  Ca
2-activated K
LAD  left anterior descending coronary artery
L-NAME  NG-nitro-L-arginine methyl ester
MAP  mitogen-activated protein
MBP  myelin basic protein
MI  myocardial infarct
MPO  myeloperoxidase
NO  nitric oxide
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infarct zone. Infarct size was expressed as the percentage of
the infarct zone that is contiguous with area at risk.
Regional myocardial blood flow was determined by the
microsphere technique (19).
Measurement of activity of MAP kinases. For the mea-
surement of activity of MAP kinases, 0.5 g myocardial tissue
was homogenized, and an in vitro kinase assay was carried
out. Extracts from tissue homogenization were subjected to
immunoprecipitation with anti-p38 MAP kinase antibody
bound to protein A/agarose (Amersham Pharmacia
Biotech, Piscataway, New Jersey), c-Jun fusion protein
beads (Cell Signaling Technology, Beverly, Massachusetts),
anti-ERK 1/2 antibody bound to protein A/agarose (Up-
state Biotechnology, Waltham, Massachusetts). The immu-
noprecipitates were collected and washed extensively. Im-
munoprecipitates of anti-p38 MAP kinase and anti-ERK
1/2 antibody were mixed with 2 mg/ml dephosphorylated
MAP kinase-2 activated protein and myelin basic protein
(MBP), respectively, as a substrate, and 200 mmol/l aden-
osine triphosphate (ATP) for kinase assay. Pellets precipi-
tated with glutathion-S-transferase/c-Jun/sepharose were
mixed with 100 mmol/l ATP. Then, the reaction mixtures
were further incubated for 30 min at 30°C. The kinase
reaction was terminated by boiling in an appropriate volume
of sodium dodecyl sulfate (SDS) sample buffer. The reaction
components were separated by SDS/polyacrylamide gel
electrophoresis and transferred to a nitrocellulose mem-
brane. The phosphorylated MAPKAP kinase-2, c-Jun and
MBP were detected by anti-phospho-MAPKAP kinase-2
(Upstate Biotechnology), antiphosphorylated c-Jun (Cell
Signaling Technology), and antiphosphorylated MBP (Up-
state Biotechnology) antibodies, respectively. The total
content of p38 MAP kinase, c-Jun, or ERK in the samples
was also determined by immunoblot analysis using anti-p38
MAP kinase, c-Jun, and ERK 1/2 antibodies. The band
density was analyzed by NIH image software.
Measurement of myocardial myeloperoxidase (MPO)
activity. Several myocardial tissue samples were taken from
ischemic areas or nonischemic areas in each dog, frozen in
liquid nitrogen and stored at 45°C until assay. The
technical procedure was previously described (20). One unit
of MPO activity was defined as that which degraded 1 mol
hydrogen peroxide per minute at 25°C.
Statistical analysis. Data are expressed as the mean value
 SE. Statistical significance was performed with analysis of
variance, and if differences were revealed among groups,
they were assessed using the Fisher-Irwin test. A value of
p  0.05 was considered statistically significant.
RESULTS
Assignments and exclusions. The number of dogs as-
signed and excluded in each group is shown in Table 1.
Effects of raloxifene on infarct size. Heart rate and mean
arterial blood pressure remained stable among the experi-
mental groups throughout the study (Fig. 1). Both coronary
blood flow and coronary perfusion pressure in all experi-
mental groups did not significantly change during raloxifene
infusion, although coronary blood flow in the raloxifene
(5 g/kg per min) group tended to increase at the end of
raloxifene treatment, but it was not statistically significant,
and the area at risk and collateral blood flow were also
similar among all groups (Table 2).
The infarct size in the control group was 40.9  3.9% of
the area at risk, and vehicle did not have an infarct
size–limiting effect (infarct size 37.4  4.8%). Raloxifene (5
g/kg per min) significantly reduced the infarct size com-
pared with that of the control group (infarct size 7.2 
2.5%, p  0.01), whereas a low dose of raloxifene (0.5
g/kg per min) did not mediate the effect (infarct size 38.3
 2.0%). Figure 2 revealed that the infarct size–limiting
effect was attenuated by either L-NAME (infarct size 21.4
 4.4%, p  0.05 vs. control or raloxifene [5 g/kg per
min]) or CTX (infarct size 20.5  5.0%, p  0.05 vs.
control or raloxifene [5 g/kg per min]) and completely
abolished by L-NAME  CTX (infarct size 37.7  5.8%,
p  0.05 vs. L-NAME or CTX and p  0.01 vs. raloxifene
[5 g/kg per min]). Only administration of the inhibitors
L-NAME and CTX did not exaggerate the infarct size (40.5
 4.1%) compared with that of the control group.
Table 1. Number of Dogs Assigned to and Excluded From Each Group for Measurement of Infarct Size
Dogs Originally
Assigned
(n)
Dogs Used for
Data Analysis
(n)
Reason for Exclusion
VF (>2)
During 6 h
Reperfusion (n)
Death Due to
VF (n)
High Collateral
Blood Flow
(>15 ml/100 g per min)
Saline 9 7 1 1 0
Vehicle 9 7 1 0 1
Raloxifene (0.5 g/kg per min) 6 5 1 0 0
Raloxifene (5 g/kg per min) 9 8 0 0 1
Raloxifene (5 g/kg per min)  L-NAME 7 5 0 2 0
Raloxifene (5 g/kg per min)  CTX 7 5 1 0 1
Raloxifene (5 g/kg per min)  L-NAME  CTX 7 5 1 1 1
L-NAME  CTX 8 6 1 1 0
CTX  charybdotoxin; L-NAME  NG-nitro-L-arginine methyl ester; VF  ventricular fibrillation.
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Effects of raloxifene on VF during the reperfusion peri-
od. Pretreatment of dogs with raloxifene (5 g/kg per min)
significantly reduced the overall incidence of VF during the
6-h reperfusion period. This effect was abolished by
L-NAME and CTX administered alone or together with
raloxifene. At a dose of 0.5 g/kg per min, raloxifene did
not decrease the incidence of VF (Table 3).
Effects of raloxifene on MAP kinase activity during
ischemia. Figure 3A shows the three major MAP kinase
activities in each group, and Figure 3B demonstrates the
representative results. Activities of p38 MAP kinase, JNK,
and ERK in the group with ischemia were all significantly
increased by 8.1  1.2%, 10.4  3.8% and 11.7  4.9%,
respectively, compared with the group with no ischemia.
Activities of JNK and ERK were not different between the
groups with ischemia and raloxifene pretreatment before
ischemia, but only p38 activity was significantly reduced in
the group with raloxifene pretreatment before ischemia,
compared with the group with ischemia. Attenuation of p38
MAP kinase activity by pretreatment with raloxifene in the
Figure 1. The changes in heart rate and mean arterial pressure during the experiment in each group are shown. No difference in heart rate or mean arterial
pressure was observed throughout the experiment between the groups. CTX  charybdotoxin; L-NAME  NG-nitro-L-arginine methyl ester.
Table 2. Coronary Hemodynamics, Collateral Blood Flow and Area at Risk Among Experimental Groups
Group
Before Treatment
With Raloxifene Before Ischemia
At End of
Raloxifene Infusion
Collateral
Blood Flow
(ml/100 g
per min)
Area at
Risk (%)
CPP
(mm Hg)
CBF
(ml/100 g
per min)
CPP
(mm Hg)
CBF
(ml/100 g
per min)
CPP
(mm Hg)
CBF
(ml/100 g
per min)
Control 102  5 86  5 104  5 88  6 98  8 85  7 10.5  1.1 41  3
Vehicle 105  6 85  6 106  6 81  9 105  5 87  13 10.2  0.9 41  1
Raloxifene (0.5 g/kg per min) 107  4 86  6 110  6 90  5 100  7 89  11 9.3  1.3 45  6
Raloxifene (5 g/kg per min) 103  7 86  4 108  4 84  9 99  3 92  9 10.4  0.7 44  2
Raloxifene (5 g/kg per min)  L-NAME 108  4 85  5 108  4 82  9 104  6 85  4 10.4  1.7 43  1
Raloxifene (5 g/kg per min)  CTX 105  5 84  5 105  6 86  5 104  9 84  6 10.1  1.3 44  3
Raloxifene (5 g/kg per min)  CTX 102  8 86  7 105  3 87  5 100  4 84  7 9.6  1.3 42  1
L-NAME  CTX 106  8 88  9 107  6 87  10 101  8 87  9 9.4  1.1 45  4
Data are presented as the mean value  SE. There was no significant difference in any value among all groups.
CBF  coronary blood flow; CPP  coronary perfusion pressure; other abbreviations as in Table 1.
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ischemic state was abolished by co-administration of
L-NAME and CTX with raloxifene.
Myocardial MPO activity. Data on MPO activity for the
ischemic and nonischemic regions of all experimental
groups are shown in Table 4. These results showed that
MPO activity significantly decreased only in the raloxifene
(5 g/kg per min) group, compared with the control group,
suggesting that raloxifene reduced myocardial ischemia-
reperfusion injury by attenuation of MPO activity.
DISCUSSION
We have shown that raloxifene reduces the MI size and the
incidence of ischemia- and reperfusion-induced VF in dogs
and that these cardioprotective effects are blocked by either
inhibition of NO synthase or antagonism of KCa channels.
Moreover, only treatment with L-NAME and CTX does
not exacerbate the infarct size and incidence of VF, com-
pared with the control group. These results suggest that
augmentation of endogenous NO release and opening of
KCa channels induced by raloxifene synergistically contrib-
ute to the alleviation of irreversible ischemia-reperfusion
injury. Furthermore, p38 MAP kinase activity in myocardial
ischemia was reduced by raloxifene, suggesting that inhibi-
tion of p38 MAP kinase–signaling pathways is cardiopro-
tective, as previously described (13,14), and this may partly
explain the effects of raloxifene on ischemia-reperfusion injury.
Mechanisms of cardioprotective effects against ischemia-
and reperfusion-induced injury mediated by NO and
opening of KCa channels. The present results demonstrate
that raloxifene attenuated infarct size and incidence of VF
during reperfusion by cardioprotective mechanisms medi-
ated by both NO and the opening of KCa channels.
Potentiation of NO release may be an effective pharmaco-
logic intervention to limit MI size, given that the adminis-
tration of an NO donor markedly attenuates ischemia-
Figure 2. Infarct size as a percentage of the area at risk in the various experimental groups. Data from individual animals and mean  SE values are shown.
*p  0.01 vs. control group. †p  0.05 vs. raloxifene (5 g/kg per min) group. ‡p  0.05 vs. control group. §p  0.01 vs. raloxifene (5 g/kg per min)
group. CTX  charybdotoxin; L-NAME  NG-nitro-L-arginine methyl ester.
Table 3. Percentage of Survival and Incidence of Ventricular
Fibrillation in Each Group
Group
Survival
(n/N)
Incidence
of VF
Control 88.9% (8/9) 44.4%
Vehicle 100% (9/9) 33.3%
Raloxifene (0.5 g/kg per min) 100% (6/6) 33.3%
Raloxifene (5 g/kg per min) 100% (9/9) 11.1%*
Raloxifene (5 g/kg per min)  L-NAME 71.4% (5/7) 42.9%
Raloxifene (5 g/kg per min)  CTX 100% (7/7) 28.6%
Raloxifene (5 g/kg per min)
 L-NAME  CTX
85.7% (6/7) 42.9%
L-NAME  CTX 87.5% (7/8) 37.5%
*p  0.05 vs. control group.
Abbreviations as in Table 1.
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reperfusion injury (21,22). Several possible mechanisms may
underlie the beneficial effects of NO on infarct size. First,
because NO regulates the membrane Ca2 current of
cardiac cells (23), it may reduce the severity of ischemia by
inhibiting the cytosolic accumulation of Ca2. Second, NO
may also reduce oxygen-derived free radical generation by
decreasing lipolysis, thereby limiting the generation of
radicals through lipid peroxidation (24). It is not clear how
raloxifene increases the release of NO in the reperfused
heart, but a previous report demonstrated that raloxifene
caused an immediate and marked production and release of
NO in human endothelial cells (25). Increases in the cardiac
NO level can also provoke protective effects against VF
during reperfusion.
Opening of KCa channels may hyperpolarize the cellular
membrane and reduce Ca2 overload during ischemia and
reperfusion, similar to the protective effect of ATP-sensitive
K channels (26), in addition to its coronary vasodilatory
effect (17). The precise mechanism by which the opening of
KCa channels reduces VF during reperfusion is unknown.
Although opening of KCa channels may reduce the duration
of action potentials during coronary occlusion, resulting in
an arrhythmogenic effect, this opening reduces Ca2 over-
load in cardiomyocytes as a result of a hyperpolarized
membrane potential.
Role of p38 MAP kinases in infarct size–limiting and
anti-arrhythmic effects. We have shown that three major
MAP kinases, including p38 MAP kinase, JNK, and ERK,
were activated by ischemia and that raloxifene reduced only
p38 MAP kinase activity, but not JNK and ERK, in canine
hearts. Activation of p38 MAP kinase, JNK, and ERK in
cardiomyocytes subjected to ischemia was previously re-
ported (15,16), but the present study is the first to demon-
strate an increase of MAP kinase activity in ischemic canine
Figure 3. (A) Increases in p38 MAP kinase, JNK, and ERK activities in each group, compared with the “no ischemia” group, are shown (mean  SE, n 
3 in each group). These MAP kinases were all activated during ischemia, whereas only p38 MAP kinase was inhibited by infusion of raloxifene into the
coronary artery. The activities of the three kinases have been normalized to their total content. *p  0.01 vs. group with no ischemia. †p  0.05 vs. group
with ischemia. ‡p  0.05 vs. group with raloxifene pretreatment without inhibitors (e.g., L-NAME and CTX). (B) Representative results in each kinase
are shown.
Table 4. Myeloperoxidase Activity of the Reperfused
Myocardium
Ischemic Area
(U/g protein)
Nonischemic Area
(U/g protein)
Control 20.1  3.1 4.6  1.1
Vehicle 19.9  5.1 3.8  1.3
Raloxifene (0.5 g/kg per min) 22.9  4.9 4.4  1.2
Raloxifene (5 g/kg per min) 6.6  1.9* 4.7  1.2
Raloxifene (5 g/kg per min)
 L-NAME
14.4  2.9 5.5  2.2
Raloxifene (5 g/kg per min)
 CTX
11.5  2.3 4.8  2.5
Raloxifene (5 g/kg per min)
 L-NAME  CTX
25.9  2.8 3.1  0.8
L-NAME  CTX 22.1  2.5 3.7  0.7
*p  0.05 vs. control group. Data are presented as the mean value  SE.
Abbreviations as in Table 1.
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hearts in vivo. Activation of ERK may be part of a “survival
pathway,” whereas activation of p38 MAP kinase and JNK
represents a “death pathway” in the heart (27). In our study,
increased activity of ERK was equal to that of JNK and less
than that of p38 MAP kinase (Fig. 3). It is possible that the
beneficial effects of ERK against ischemia might be abro-
gated by activation of both p38 MAP kinase and JNK in the
ischemic heart. Some reports demonstrated that inhibition
of p38 MAP kinase was effective for cardioprotection
(13,14,28). In our study, p38 MAP kinase activation was
attenuated by raloxifene during ischemia, and it may be
reasonable that raloxifene has MI size–limiting and anti-
arrhythmic effects by inhibition of the p38 MAP kinase–
signaling pathway.
p38 MAP kinase regulates transcription factors, which
respond to transcriptional changes in nuclei. In this study,
there was a rapid and pronounced effect of raloxifene against
ischemia-reperfusion injury, suggesting that raloxifene de-
velops its effect by non-genomic means. p38 MAP kinase
mediates myocardial ischemia-reperfusion–induced cyto-
kines and free radical production (29,30), neutrophil acti-
vation (31), and platelet aggregation (32). It is possible to
explain that the infarct size–limiting and anti-arrhythmic
effects induced by raloxifene in our early-phase experiments
are partly due to a reduction of ischemia-induced neutrophil
activation accompanied by p38 MAP kinase inhibition,
because the increased myocardial MPO activity of the
ischemic area was actually diminished to the level of the
nonischemic area by raloxifene infusion (5 g/kg per min)
(Table 4). Although the relationship between p38 MAP
kinase, KCa channels, and NO is unclear, co-administration
of L-NAME and CTX with raloxifene abolished the atten-
uation of p38 MAP kinase activity by treatment with
raloxifene in our present study (Fig. 3), suggesting that p38
MAP kinase activity may be inhibited by NO and opening
of KCa channels under ischemic stress. In contrast, we could
not deny the possible mechanism that inhibition of p38
MAP kinase activity by raloxifene in ischemia may result in
both an increased NO level and opening of KCa channels,
because inhibition of p38 MAP kinase activity reduces the
production of free radicals during ischemia and reperfusion,
subsequently increasing the impaired NO synthase activity
(29). Nitric oxide, opening of KCa channels, and inhibition
of p38 MAP kinase possibly contribute to the mechanisms
of cardioprotection against ischemia and reperfusion.
Clinical implications. To the best of our knowledge, this
is the first report to demonstrate the MI size–limiting and
anti-arrhythmic effects of raloxifene. In another report (33),
idoxifene, one of the selective estrogen modulators, like
raloxifene, had a beneficial effect on vascular remodeling in
the balloon denudation rat model. Together with this
action, raloxifene could be a good therapeutic drug for
ischemic heart diseases. Moreover, raloxifene would be
expected to be more advantageous and selective for the
cardiovascular system, compared with estrogen, and it is
possible to use raloxifene not only in postmenopausal
women but also in premenopausal women with coronary
heart diseases.
Acknowledgments
We thank Hideki Koyama, Akiko Ogai, Tomi Fukushima,
and Junko Yamada for their technical assistance and advice.
Reprint requests and correspondence: Dr. Koichi Node, De-
partment of Internal Medicine and Therapeutics, Osaka Univer-
sity Graduate School of Medicine, 2-2 Yamada-oka, Suita, 565-
0871, Osaka, Japan. E-mail: node@medone.med.osaka-u.ac.jp.
REFERENCES
1. Stampfer MJ, Colditz GA, Wilett WC, et al. Postmenopausal
estrogen therapy and cardiovascular disease: ten-year results from the
Nurses’ Health Study. N Engl J Med 1991;325:756–62.
2. Node K, Kitakaze M, Kosaka H, Minamino T, Funaya H, Hori M.
Amelioration of ischemia- and reperfusion-induced myocardial injury
by 17-estradiol: role of nitric oxide and calcium-activated potassium
channels. Circulation 1997;96:1953–63.
3. Node K, Kitakaze M, Kosaka H, et al. Roles of NO and Ca2-
activated K channels in coronary vasodilation induced by 17-
estradiol in ischemic heart failure. FASEB J 1997;11:793–9.
4. Boyle P, Maisonneuve P, Autier P. Update on cancer control in
women. Int J Gynaecol Obstet 2000;70:263–303.
5. Douketis JD, Gordon M, Johnston M, Julian JA, Adachi JR, Ginsberg
JS. The effects of hormone replacement therapy on thrombin gener-
ation, fibrinolysis inhibition, and resistance to activated protein C:
prospective cohort study and review of the literature. Thromb Res
2000;99:25–34.
6. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on
bone mineral density, serum cholesterol concentrations, and uterine
endometrium in postmenopausal women. N Engl J Med 1997;337:
1641–7.
7. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud
C. A controlled trial of raloxifene (LY139481) HCl: impact on bone
turnover and serum lipid profile in healthy postmenopausal women.
J Bone Miner Res 1996;11:835–42.
8. Heaney RP, Draper MW. Raloxifene and estrogen: comparative
bone-remodeling kinetics. J Clin Endocrinol Metab 1997;82:3245–9.
9. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum
lipids and coagulation factors in healthy post-menopausal women.
JAMA 1998;279:1445–51.
10. Ettinger B, Black DM, Mitlak BH, et al, the Multiple Outcomes of
Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral
fracture risk in postmenopausal women with osteoporosis treated with
raloxifene: results from a 3-year randomized clinical trial. JAMA
1999;282:637–45.
11. Figtree GA, Lu Y, Webb CM, Collins P. Raloxifene acutely relaxes
rabbit coronary arteries in vitro by an estrogen receptor–dependent
and nitric oxide–dependent mechanism. Circulation 1999;100:1095–
101.
12. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways.
Curr Opin Cell Biol 1997;9:180–6.
13. Ma XL, Kumar S, Gao F, et al. Inhibition of p38 mitogen-activated
protein kinase decreases cardiomyocyte apoptosis and improves cardiac
function after myocardial ischemia and reperfusion. Circulation 1999;
99:1685–91.
14. Mackay K, Mochly-Rosen D. An inhibitor of p38 mitogen-activated
protein kinase protects neonatal cardiac myocytes from ischemia. J Biol
Chem 1999;274:6272–9.
15. Knight RJ, Buxton DB. Stimulation of c-Jun kinase and mitogen-
activated protein kinase by ischemia and reperfusion in the perfused rat
heart. Biochem Biophys Res Commun 1996;218:83–8.
16. Yue TL, Wang C, Gu JL, et al. Inhibition of extracellular signal–
regulated kinase enhances ischemia/reoxygenation-induced apoptosis
in cultured cardiac myocytes and exaggerates reperfusion injury in
isolated perfused heart. Circ Res 2000;86:692–9.
1004 Ogita et al. JACC Vol. 40, No. 5, 2002
Effect of Raloxifene on Myocardial Injury September 4, 2002:998–1005
17. Node K, Kitakaze M, Kosaka H, et al. Plasma nitric oxide end
products are increased in the ischemic canine heart. Biochem Biophys
Res Commun 1995;211:370–4.
18. Node K, Kitakaze M, Kosaka H, Minamino T, Hori M. Bradykinin
mediation of Ca2-activated K channels regulates coronary blood
flow in ischemic myocardium. Circulation 1997;95:1560–7.
19. Mori H, Haruyama S, Shinozaki Y, et al. New nonradioactive
microspheres and more sensitive x-ray fluorescence to measure regional
blood flow. Am J Physiol 1992;263:H1946–57.
20. Asanuma H, Kitakaze M, Funaya H, et al. Nifedipine limits infarct
size via NO-dependent mechanisms in dogs. Basic Res Cardiol
2001;96:497–505.
21. Ma XL, Weyrich AS, Lefer DJ, Lefer AM. Diminished basal nitric
oxide release after myocardial ischemia and reperfusion promotes
neutrophil adherence to coronary endothelium. Circ Res 1993;72:403–
12.
22. Lefer DJ, Nakanishi K, Johnston WE, Vinten-Johansen J. Antineu-
trophil and myocardial protecting action of a novel nitric oxide donor
after acute myocardial ischemia and reperfusion in dogs. Circulation
1993;88:2337–50.
23. Mery PF, Pavoine C Belhassen, Pecker F, Fishmeister R. Nitric oxide
regulates cardiac Ca2 current: involvement of cGMP-inhibited and
cGMP-stimulated phosphodiesterases through guanylyl cyclase acti-
vation. J Biol Chem 1993;268:26286–95.
24. Gaudiot N, Ribiere C, Jaubert AM, Giudicelli Y. Endogenous nitric
oxide is implicated in the regulation of lipolysis through antioxidant-
related effect. Am J Physiol 2000;279:C1603–10.
25. Simoncini T, Genazzani AR. Raloxifene acutely stimulates nitric oxide
release from human endothelial cells via an activation of endothelial
nitric oxide synthase. J Clin Endocrinol Metab 2000;85:2966–9.
26. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium
channels prevents myocardial preconditioning in dogs. Circ Res
1992;70:223–33.
27. Abe J, Baines CP, Berk BC. Role of mitogen-activated protein kinases
in ischemia and reperfusion injury: the good and the bad. Circ Res
2000;86:607–9.
28. Sanada S, Kitakaze M, Papst PJ, et al. Role of phasic dynamism of p38
mitogen-activated protein kinase activation in ischemic precondition-
ing of the canine heart. Circ Res 2001;88:175–80.
29. Cain BS, Meldrum DR, Meng X, et al. p38 MAPK inhibition
decreases TNF-alpha production and enhances postischemic human
myocardial function. J Surg Res 1999;83:7–12.
30. Lal AS, Clifton AD, Rouse J, Segal AW, Cohen P. Activation of the
neutrophil NADPH oxidase is inhibited by SB 203580, a specific
inhibitor of SAPK2/p38. Biochem Biophys Res Commun 1999;259:
465–70.
31. Ciesla DJ, Moore EE, Gonzalez RJ, Biffl WL, Silliman CC. Hyper-
tonic saline inhibits neutrophil (PMN) priming via attenuation of p38
MAPK signaling. Shock 2000;14:265–70.
32. Saklatvala J, Rawlinson L, Waller RJ, et al. Role for p38 mitogen-
activated protein kinase in platelet aggregation caused by collagen or a
thromboxane analogue. J Biol Chem 1996;271:6586–9.
33. Yue TL, Vickery-Clark L, Louden CS, et al. Selective estrogen
receptor modulator idoxifene inhibits smooth muscle cell proliferation,
enhances reendothelialization, and inhibits neointimal formation in
vivo after vascular injury. Circulation 2000;102 Suppl III:281–8.
1005JACC Vol. 40, No. 5, 2002 Ogita et al.
September 4, 2002:998–1005 Effect of Raloxifene on Myocardial Injury
